The results of a 10-year, international clinical trial led by Dr. Christopher J. Cooper, professor and chair of the UT Departmetn of Medicine, will alter the way physicians treat people with specific types of hypertension.
The Cardiovascular Outcomes in Renal Atherosclerotic Lesions trial, known as CORAL, revealed that opening narrowed arteries to the kidney with a stent combined with medication didn’t help patients any more than taking medicine alone. The results were announced Monday, Nov. 18 at the American Heart Association’s scientific conference in Dallas.
“Stenting of atherosclerotic renal stenosis has been reasonable, despite several negative studies, because other studies suggested it might lower blood pressure and stabilize kidney function,” Cooper says in the official announcement from the AHA. “But in our study, opening narrowed kidney arteries with stents provided no additional benefit when added to medications that lower blood pressure, control cholesterol levels and block substances involved in blood clotting.”
In an article in today’s Toledo Blade, Dr. Cooper describes the research in detail and notes that he already is adjusting his treatment plans based on the results.
The news has been reported by the Associated Press, Washington Post, Forbes, Bloomberg, and other national news outlets, in additional to some international attention by the Montreal Gazette and Ottawa Citizen in Canada and numerous medical websites, such as WebMD’s Medscape.
Learn more about the CORAL clinical trial at coralclinicaltrial.org.